The Lyon-based deeptech company Ablatom, a spin-off from the French National Center for Scientific Research (CNRS) and the Institut Lumière Matière (Université Claude Bernard Lyon 1), has adapted Libs (Laser Induced Breakdown Spectroscopy) laser technology for real-time biomedical analysis for the first time. Initially designed for space exploration, this innovation was used in November 2024 at the Grenoble University Hospital Center to analyze tumors directly in the operating room.

A laser pulse takes a few nanograms of material from the surface of living tissue. Transformed into plasma, this material emits light that is analyzed to identify its chemical components. This technology supports targeted cancer therapies by measuring their effectiveness at the very moment of the interventions.

In addition to the medical sector, the Libs laser opens up prospects in industry and mining. Its ability to analyze inaccessible surfaces without contact makes it a valuable tool. For example, it can quickly detect chemical anomalies, such as silicon overload in the respiratory tract, or optimize ore extraction by reducing analysis times.

Since its creation in 2017, Ablatom has relied on two patents and a license for its laser microscope and data processing software. Running as a profitable concern, the business plans to double its workforce by 2025 and is now targeting the North American market.